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                       INTRODUCTION 
 
Capsules
1
 
The most versatile of all dosage forms is the capsule. The administration of 
liquid and solid drugs enclosed in hard gelatin capsules is one of the most frequently 
utilized dosage forms in western medicine. 
Definition: 
Capsules are easier to swallow and are used by manufacturers when the drug 
can’t be compacted into a solid tablet. They are also useful when the drug needs to be 
mixed with oil or other liquid to aid absorption in the body. It is normally a shell or 
container made of gelatin that contains the drug. 
Explanation 
A capsule is made of certain materials that stop the medication from dissolving 
in the acidic conditions of the stomach and the alkaline conditions of the small intestine. 
This is so the drug reaches the walls of the stomach/intestine and passes through into 
the blood stream. 
 
Capsules are unit doses of drugs enclosed within soluble shells of gelatin or 
similar material, intended to be swallowed whole. Hard capsules were invented in 1833 
in America. They were {and are today} made of gelatin and consist of two parts, a body 
and a lid [they were supplied readymade but were filled in the pharmacy]. 
Capsules are available in many different sizes and shapes and can be used for 
administration of powders, semisolids and liquids.  
   
A capsule is a smooth, slippery, easy to swallow and tasteless shell of any 
convenient shape containing drugs. Capsules are made principally of gelatin blends and 
may contain small amounts of certified dyes, opaquing agents, plasticizer and 
preservatives. ( Leon Lachman 1991 ). 
a) It is tasteless and particularly useful for drugs having unpleasant odour or taste. 
b) It is economically produced in large quantities and has many pleasing colours. 
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c) It provides ready availability of the contained drug. 
d) Manufacturing is easier as it uses minimal excipients and only little pressure is 
required while compacting as compared to tabletting. 
 
Gelatin capsules
1
 are an elegant and widespread pharmaceutical dosage form; they 
enable drugs to be easily and safely administered whether in liquid, paste or solid form. 
At the same time, pharmaceuticals in capsule form have a high degree of 
bioavailability. Pharmaceutical capsules enable active ingredients to be formulated with 
long shelf lives, protected from light and oxygen. Depending on the nature of the 
substance to be encapsulated, either hard- or soft capsules can be used. Soft capsules are 
the more suitable for liquid or paste fillings based on oil whilst hard capsules are used in 
general for powdered substances. 
 
Types of capsules The main types of capsules are:  
Hard gelatin capsules 
2, 3
 : The capsule shell The shell of hard gelatin capsules 
basically consists of gelatin, plasticizers and water. Modern day shells may, in addition, 
consist of preservatives, colours, opacifying agents, flavours, sugars, acids, enteric 
materials etc. The gelatin is marketed in a large number of varieties and a specific 
quality and gelatin having specified gel strength, viscosity, iron content etc. should be 
selected for capsules. The variations in gelatin properties arise because of changes in 
molecular weights and methods followed in conversion into gelatin. The average 
molecular weight of gelatin, varies between 20,000 and 2,00,000. Two popular grades 
of gelatin, Pharmagel-A and Pharmagel-B, are acid processed and alkali processed 
respectively. They have differing isoelectric points (Pharmagel-A: pH. 4.8 to 5.2, 
Pharmagel-B: ph 6.5 to 9.5). For capsule shells generally a mixture derived from pork 
skin and bones is used. Pork skin gelatin contributes plasticity while bone gelatin gives 
firmness. However, in using bone gelatin its calcium phosphate content should be 
watched since undue amounts can make capsules hazy. One important reason for the 
exclusive use of gelatin for making hard and soft capsules is its solubility characteristics 
in stomach fluids. It absorbs cold water readily, though the rate of absorption depends 
 3 
 
upon moisture content of gelatin. Bloom Strength Bloom strength is an empirical gel 
strength measure, which give an indication of the firmness of gel It is measured by a 
bloom gelometer It determines the weight in grams required to depress a standard 
plunger a fixed distance into the surface of 6 2/3 % w/w gel under standard conditions 
Bloom strength in the range of 150-280 g are considered suitable for capsules. 
 
The plasticizers used are glycerin, sorbitol etc. The exact proportions of gelatin 
and plasticizers have to be determined on the basis of the use of capsules and their 
storage conditions. Preservatives, if included, are generally a mixture of methylparaben 
(4 part) and propylparaben (1 part ) to the extent of 0.2%. Flavours, if added, should not 
exceed 2% and are generally ethyl vanillin or essential oils. Sugar, if included, may be 
up to 5% of give the gelatin shell desirable chewable characteristics. The capsule shells 
are nowadays produced on mass scale by sophisticated machinery. Fundamentally 
speaking, in every machinery, pairs of pins corresponding to the bodies and the caps of 
the capsules are dipped in heated gelatin solutions containing the necessary additives. 
The dipping is followed by withdrawal of pins and their rotation a few times to 
distribute the solutions evenly. Cold air is simultaneously blown on the rotating pins to 
firm up the gelatin shells. These pins are, thereafter, passed though series of kilns with 
controlled rates of drying.  
After drying, the bodies and caps are removed from pins by mechanical jaws 
and are trimmed to appropriate lengths by rotating blades. Finally the caps are placed on 
the bodies. 
 
The capsules shells should be stored under controlled conditions of temperature 
and humidity. The normal moisture content of shell is 10 to 15%. Under conditions of 
low humidity they may soften and grow tacky. The shells for human use are marketed 
in 8 size depends upon its density and compressibility. Normally the shell 
manufacturers give a guidance of the approximate quantities of selected drugs that can 
be contained in different sizes. 
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   Figure: 1 Hard gelatin capsules 
Hard gelatin capsule manufacturing 
2,3,4
 ( Loyd V. Allen, 2008 ) 
1. Once raw materials have been received and released by Quality Control, the gelatin 
and hot demineralized water are mixed under vacuum in Stainless Steel Gelatin Melting 
System 
2. After aging in stainless steel receiving tanks, the gelatin solution is transferred to 
stainless steel feed tanks. 
3. Dyes, opacifants, and any needed water are added to the gelatin in the feed tanks to 
complete the gelatin preparation procedure. The feed tanks are then used to gravity-feed 
gelatin into the Capsule Machine. 
6. The Pin Bars pass through the upper and lower kilns of Capsule Machine Drying 
System. Here gently moving air which is precisely controlled for volume, temperature, 
and humidity, removes the exact amount of moisture from the capsule halves.  
7. Precision controls constantly monitor humidity, temperature, and gelatin viscosity 
throughout the production process 
8. Once drying is complete, the Pin Bars enter the Table section which positions the 
capsule halves for stripping from the Pins in the Automatic section. 
9. In the Automatic section, capsule halves are individually stripped from the Pins. 
10. The cap and body lengths are precisely trimmed to a ±0.15 mm tolerance. 
11. The capsule bodies and caps are joined automatically in the joiner blocks. 
12. Finished capsules are pushed onto a conveyer belt which carries them out to a 
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container. 
13. Capsule quality is monitored throughout the production process including size, 
moisture content, single wall thickness, and colour. 
14. Capsules are sorted and visually inspected on specially designed  Inspection 
Stations. 
15. Perfect capsules are imprinted with the client logo on high-speed capsule printing 
machines. Capsules are now ready to be sterilized and packaged.  
Soft capsules 
1
 :  
The designation soft capsule implies that the outer wall contains, apart from 
gelatin, a plasticiser, the degree of softness and elasticity of which depends on the 
quantity and type of plasticizer used, the residual moisture and the thickness of the 
capsule wall. Soft capsules tend to have thicker walls than hard capsules. Glycerin and 
sorbitol, or a mixture of both, are normally used as plasticizers. 
 
   Figure 2 Soft gelatin capsules 
Soft Gelatin Capsule Manufacturing 
1,5,6
 
In the manufacturing of soft gelatin capsules the capsulating process works in 
the following manner: warm liquid gelatin is spread over a slowly revolving stainless 
steel drum which is about 24‖ in diameter. This drum is exposed to 400 CFM of 57- 
59°F ir at 20% RH. The cool, dry air congeals the gelatin as the drum rotates so that a 
tacky, elastic band rolls off of the other end. This thin band is then automatically 
formed into capsules; filled with medicine, vitamins or other products; sealed; and 
dropped into a tray.   
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If the air blowing against the drum has too low a temperature, the gelatin will set 
too rapidly and become brittle which can cause the manufacturing process to grind to a 
halt. Too high of an air velocity will disturb the consistent thickness of the gelatin 
ribbon being formed. If the air temperature and humidity are too high, or the air velocity 
is too low, the gelatin will not solidify into a ribbon. Thus, the need for constant control 
of the air being introduced to the drum is critical in the process.  
The extent of moisture to be removed during drying depends upon the size of the 
capsule, the number of capsules, and the period of time over which this moisture can be 
removed. Typically the environment to be maintained for effective and rapid drying 
corresponds to a dew point of 25° F or an absolute humidity level of 20 grains per 
pound of air.  
 
Table: 1 Typical design conditions for manufacturing of soft gelatin  
                              capsules   
 
Temperature Humidity 
78°F 15% RH 
68°F 20% RH 
  
 In order to achieve the controlled air requirement listed above, refrigeration 
equipment alone becomes uneconomical, impractical and cumbersome to design, 
operate and maintain. On the other hand desiccant type dehumidifiers combined with 
refrigeration can offer a simple and economical solution to controlling both temperature 
and humidity levels as low as necessary.  
 
Dry-Air desiccant dehumidifiers have been utilized in many capsulating and soft 
gel manufacturing applications all over the world resulting in millions of dollars saved 
annually. 
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           Table: 2 Different capsule sizes and their capacities 
Size Outer diameter(mm) 
Height/locked length 
(mm) 
Actual volume 
(ml) 
000 9.97 26.14 1.37 
00 8.53 23.30 0.95 
0 7.65 21.70 0.68 
1 6.91 19.40 0.50 
2 6.35 18.00 0.37 
3 5.82 15.90 0.30 
4 5.31 14.30 0.21 
5 4.91 11.10 0.13 
 
Limitations: 
Capsules are not suitable for drugs that are very soluble, such as the salts 
(potassium chloride, potassium bromide, ammounium chloride). In these situations, the 
fluid penetrating the capsule rapidly dissolves the salt and creates a high concentration 
solution, which can cause nausea and vomiting when it contacts the gastric mucosa. 
 
Strongly efflorescent or deliquescent materials are not suitable for capsules since 
efflorescent materials may cause capsules to soften when water is lost and strongly 
deliquescent materials may make the capsule shell brittle when the moisture is extracted 
from the shell into the powder. 
 
Manufacturing operation of capsules
1
 
The manufacturing operations can be broadly divided into four broad phases of : 
a) Drug Preparation 
b) Capsule filling 
c) Capsule finishing 
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d) Capsule packaging 
 
a) Drug preparation:  
The drug usually is in powder form, pellet form, tablet form or combination of 
any of them. 
 
b) Capsule filling:  
The capsule body and cap are separated, drug filled accurately and capsule 
body and cap are joined together to produce the filled capsule. Hand filling, hand 
filling with loader, semi-automatics machines and automatic machines are used for 
above purpose. 
 
c) Capsule finishing:  
The major operations are de-dusting / polishing, sorting, counting and 
inspection. Filled capsules require some sort of dusting and/or polishing operations, 
particularly if powder filling is done. This operation may be based on the type of 
filing equipment used, the type of powder used for filling and individual desire for 
finished appearance of capsules. 
 There are four methods used for de-dusting: 
a) Pan polishing 
b) Cloth dusting or towel polishing 
c) Brushing (with vaccum) 
d) Belt polishing (with vaccum) 
 
Sorting  
Sorting is an operation of segregating defective, under filled, over filled and 
broken open etc capsules from the proper capsules. It is usually done visually and may 
be aided by mechanical means like conveyer belts, air flow deflectors etc. it may be 
online or offline. Counting of capsules may be done by machine while filling or 
manually. Mechanical counters are used in manual counting. 
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Usually bottle filling blister packing and strip packing machines include automatic 
counters. Single or double snap capsules coupled with blister packing etc gives 
reasonable pilfer proofing. Printing of capsules is done by capsule manufacturers. 
Printing machines operate on a rotogravure process and printing may be longitudinal or 
circumferential, and in different colours. Only approved colours under drugs act are 
used. 
 
d) Capsule packing:  
Comprises of packing and sealing capsules in bottles, blisters and strips. 
 
 
       Bottle packing is resorted for large unit size (e.g. say more than 100 capsules for 
unit pack. Semiautomatic bottle filling machines with conveyer belt and associated 
work stations of labeling, stoppering, capping and sealing are available and 
indigenously and used. Most widely used bottles are glass bottles. A line here may 
comprise of 7-12 persons). 
 
Strip packing  may use paper poly, glassine poly or aluminum poly. Paper poly is 
the cheapest material but is not being used. Glassine poly and aluminum poly offer 
better product protection against moisture etc and aluminum poly is substantially used 
by the industry. The thickness of packing materials varies marginally. 
Now a days the trend is to use blister packing, it has lid foil of thermoforming 
PVC, PVC with PVDV and base foil of aluminum. It results into considerable saving of 
packing material, has better aesthetic appeal and is convenient for patient compliance, 
initial investment is however, higher.  
Secondary packing comprises of carton packing, strapping and labelling, 
Defoiling is an operation of opening rejected strips/ blisters and claiming OK capsules. 
Defoilers are available indigenously. Most, widely used method however is manual. 
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Encapsulation process
1
 
Two general methods are: Individual hand filling and capsule machine filling. 
 
Hand filling 
The powder is arranged on a suitable surface with spatula so that the thickness 
of the pile is about 2/3 the length of the capsule body. This is to avoid contacting the 
powder with the hands when punching capsules. The use of gloves or finger cots is 
recommended to minimize contact with the powder and to avoid finger prints on the 
capsules. Another option is to use of cap from a second capsule slipped over the base of 
a capsule to be filled as a holder while punching. Using this technique, capsules do not 
touch the compounding pharmacist’s hands. The capsule is pressed into the powder 
with slight rotation as it enters the power and reaches the working surface to aid in 
packing the powder. When the capsule becomes full, a slight resistance can be felt as 
the capsule is pressed through the powder. 
  
An alternative hand filling method involves blocking and dividing the powder 
into individual portions for each capsule. This approximation is not very accurate and is 
not recommended. To pack powder that will not stick in the capsules when punching, 
place each capsule base on its side and use a spatula to guide or fill the powder. Care 
must be exercised so that the capsule is not scraped or scratched. Granular materials are 
particularly difficult to punch into capsules because they are not very cohesive. 
Reducing the particle size to the point at which the powders stick together may alleviate 
this problem. 
 
Capsule filling device 
1,7
 
A number of different manually operated capsule filling devices are commercially 
available for filling up to 50 to 100 capsules at a time. These machines can be used for 
preparing smaller quantities of capsules by blocking off unused holes with an index 
card. The method of using these machines requires a careful determination of the 
capsule formation. The powder is blended as previously discussed. Empty gelatin 
capsules are placed into the device and oriented so that the cap is on top. The machine is 
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worked to separate the base form the cap and the portion of the machine holding the 
caps is removed and set aside. The capsule bases are allowed to drop into place so that 
the tops are flush with the working surface. 
 
 The powder mix is spread the powder uniformly and evenly into the capsule bases or 
the machine can be tapped to spread the powder and drop it down into the capsule bases. A 
small device consisting of several pegs on a handle can be used to tamp the powder into the 
capsule bases gently and evenly. Any remaining powder then is spread evenly over and into 
the capsule bases and tamped. These procedures are repeated until all of the powder is in the 
capsules. The capsule caps are then fitted over the machine, fixed in place, and the filled 
capsules removed, dusted using a cleaned cloth, and packaged. 
 
Hard gelatin capsules have been around for over 50 years and the range of filling 
machines to go with this is of a similar vintage. Powders with a Carr’s Index greater than 
25% are more appropriate for the dosator than for a tamping system and those of less than 
15% are more appropriate, in general, to the tamping ping. 
These are other criteria, which are important too, such as material particle size distribution 
and melting point. Over the past 20 years, increasingly accurate capsule weighers have been 
developed, with the modern ones using digital intelligent weight cells capsules of weighing 
the capsule several times, and using the average to give an accuracy of about 1-2mg. But, 
despite the best efforts of capsule shell manufacturers, limitations of the gelatin itself are 
such that the weight tolerance on an empty capsule becomes significant at low fill weights. 
For example, even on a capsule size 0 capsule weighing 96mg, the weight tolerance is 
±6mg. Currently, even when weighing empty capsules before using them on the capsule 
filer struggles to cope with the low fill weights. 
Filling mechanisms 
1.Auger fill 
Encapsulator wherein the powder / formulation is driven into the capsule 
bodies by means of a rotating auger. 
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2.Vaccum Fill 
Encapsulator wherein the powder / formulation is drawn by means of vacuum 
into cylinders containing porous pistons. The powder is scrapped flush with the open 
end of the cylinders, and then ejected into the capsule bodies via pressurized air through 
the porous piston. 
 
3.Vibratory fill 
Encapsulator wherein a perforated plate is vibrated in the bed of the powder / 
formulation. The vibratory action facilitates powder flow into the capsule bodies 
through holes in the plate. 
4.Dosing disk 
Encapsulator wherein cylindrical dosing tubes fitted with movable pistons are 
plunged into the powder / formulation bed to form soft powder plugs., The powder 
plugs are then pushed by the pistons from the dosators into the capsule bodies. 
 
Powder fill 
1.Acco fill 
Powder is charged into a hopper and is preconditioned by mixing and / 
or agitator blade(s) to assist powder deliver and flow. 
           The pre-determined amount of the powder is drawn into the fill wheel ports with 
vacuum from the supply hopper. The powder is held by the vacuum in the fill wheel 
ports until it is indexed into and dispensed into the container by use of compressed air. 
 
2.Auger 
Powder is charged into the hopper and is pre-conditioned by mixing and / or agitator 
blade (s) to assist powder delivery and flow. An auger is utilized to deliver the powder 
from the hopper into the container using a predetermined degree of revolution. 
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FILLING OPERATIONS 
 
Empty capsules 
Empty capsules are sold by sizes.the ones most commonly employed for human 
use range from size 0,the largest,to size 5,the smallest.size 00 capsules may 
occasionally be required because of the volume of material to be filled,but this size is 
not used commercially in large volume.although capsules change dimensions to some 
extent with varied moisture content and conditions encountered before use,capsules as 
received from the supplier generally have moisture content between 12 and 15% and 
these levels are maintained during storage in the original container.storage under high 
temperature conditions(above 100⁰F)must not be prolonged.exposure to high  or 
extremely low humidity conditions for extended periods after the containers are opened 
causes the capsules to either gain or lose moisture .at high moisture levels,the capsules 
absorb moisture,and may soften and become tacky.in severe cases,the capsules may 
absorb moisture,to cause them to deform under their own weight.At low moisture 
levels,they become brittle and suffer dimensional changes,which may cause handling 
problems in the filling equipment. 
                       Regarding the empty capsules only, handling is ideally carried on in areas 
within the relative humidity range of approximately 30 to 45%, since major moisture 
content changes do not  occur within these limits. If conditions drier than these are 
necessitated because of the ingredients being filled,exposures of the empty capsules 
prior to filling should be minimized.strong consideration should be given to the use of 
air conditioned facilities to control both temperatures and humidity when high- speed  
filling equipment is being operated.                 
 
SPECIAL TECHNIQUES 
Some special techniques that may be applied to the capsules as a dosage form 
include the following. 
1.Imprinting is a convenient method by which company and/or product identification 
information can be placed upon each capsule.The imprinting operation is best 
performed on the empty capsules,although filled capsules can be printed.The preference 
 14 
 
for imprinting empty capsules arises from the fact that the imprinting operation may 
occasionally damage some capsules.when filled capsules arises from the fact that the 
imprinting operation may occasionally damage some capsules.When filled capsules are 
imprinted,contamination,poor print quality,and actual damage to the imprinting 
equipment result.Various types and capacities of equipment are commercially available 
for this purpose in the united states. 
                              Hartnett offers a variety of machines with out-puts as high as 
50,000 capsules per hour.Also available is a unit that prints around the circumference of 
the capsules,as opposed to a longitudinal imprint,however,this machine operates at a 
slower rate.A lower- capacity unit(up to 250,000 capsules per hour)allows printing on 
both sides of the capsule,In different colours if desired 
                          Markem offers three models,which range from approximately 60,000 to 
250,000 capsules per hour.all three models allow for two-sided printing, 
                           Ackley offers a straight- line imprinter with an output  rate of  about 
50,000 capsules per hour. 
                          In addition,several firms,including the major empty capsule 
supplier,offer custom imprinting services. 
      All imprinting machines operate on a rotogravure process,and a wide variety  of  
colors of edible inks ,both water-and solvent-based, are commercially available. 
2.special purpose capsules are capsules to which a special treatment has been given in 
an attempt to retard the solubility in some manner .this may be done in an attempt  to 
delay absorption of the active ingredient, or to provide enteric properties.  Normal 
solubility for gelatin capsules, either empty or filled,is not defined.However, the general 
service administration ,in federal specification ,defines solubility limits for capsules as 
follows(a)water resistance-fails to dissolve in water at 20 to 30⁰c in 15 min(b)acid 
solubility-dissolves in less than 5min in 0.5%aqueous HCL(w/w)at 36 to 38⁰c. 
    None of the following is used for any commercial products as far as is known and 
cannot be seriously recommended except for experimental purposes, because of 
generally unpredictable results. 
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a. Formalin treatment has been employed to modify the solubility of gelatin capsules. 
Exposure to formalin vapours or treatment with aqueous formalin results in an 
unpredictable decrease in solubility of the gelatin film,owing to cross-linkage of the 
gelatin molecule initiated by the aldehyde. This result may also be noted if the 
product being filled contains aldehydic materials are added. Because of the nature 
of reaction, it is difficult to control the degree of insolubilisation,or indeed,to 
prevent ultimate complete solubility. 
 
b. Various coatings have been used in an effort to provide similarly modified solubility 
characteristics.These coatings include salol, shellac,cellulose acetate phthalate and 
certain resins that have usually been applied by pan coating techniques. 
            Gelatin capsules do,however,provide a convenient way to deliver pellets or 
granular material when delayed or prolonged release properties have been 
incorporated in all or portions of the material to be filled. 
 
3.separation of incompatible materials is carried out by the use of a two-phase fill in the 
capsule.one phase consists of either a soft capsule,a smaller hard capsule,a pill,or a 
suitably coated tablet that is filled in to each capsule.following this as a second 
phase,a powder fill is added in the usual manner.If this technique is used on 
commercial filling equipment,modification must be made to the filling cycle of the 
machine.These changes would include,at minimum,the necessary changes in the 
machine operation to allow materials to be loaded at two points during the filling 
cycle. 
 
 4.Recently there has been a revival of interest in the filling of conventional two-piece 
gelatin capsules with liquids and semisolids.Hard gelatin capsules were commonly used 
as early as 1890s for oils,ethereal extracts,and pill masses,but the ability to fill the 
capsules on semiautomatic and automatic equipment is a recent development.The 
```formulations used for filling are usually semisolids at ambient temperatures,which 
are melted to allow filling.or they are thixotropic formulations in which the shear 
developed in filling allows pumping,but whose high viscosity when shear is absent 
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prevents leakage after filling.Quantitative assessment of the gastric emptying of hard 
gelatin capsules filled with thixotropic liquids can be made in terms of the lag time prior 
to emptying, and the slope of the first order emptying curve. 
     
 
    INFLUENZA 
          Commonly referred to as the FLU, is an infectious disease caused by RNA   
viruses  of  the family orthomyxoviridae(the influenza viruses),that effects birds and 
mammals .The most common symptoms of the disease  are chills, fever.    sorethroat, 
musclepains. severe headache, coughing ,weakness ,discomfort. 
         Although it is confused with other influenza-like illnesses ,especially the common 
cold ,influenza is a more severe disease than the common cold caused by different type 
of virus. 
        Influenza may produce nausea and vomiting, particularly in children , but these 
symptoms are more common in the unrelated gastroenteritis ,which is sometimes,  
inaccurately referred to as ―stomach flu‖. Flu can occasionally cause either direct viral 
Pneumonia or direct bacterial pneumonia. 
      
     Typically influenza is transmitted through the air by coughs or sneezes, creating 
aerosols containing the virus. Influenza can also be transmitted by direct contact with 
bird droppings or nasal secretions ,or through contact with contaminated surfaces. 
Airborne aerosols have been thought to cause most infections, although which means of 
transmission is most important is not absolutely clear. Influenza viruses can be 
inactivated by sunlight ,disinfectants and detergents .As the virus can be inactivated by 
soap, frequent hand washing reduces the risk of infection. 
 
Influenza spreads around the world in seasonal epidemics, resulting in deaths of 
between 250,000 and 50,000 people every year ,up to millions in some pandemic years 
.On average 41,400 people died each year in the  united states between 1979 and 2001 
from influenza 
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Three influenza pandemics occurred in the 20 century and killed tens of millions 
of people, with each of these pandemics being caused by the appearance of a new strain 
of the virus  in humans .Often, these new strains appear when an existing flu virus 
spreads from humans to other animal species ,or when an existing human strain pricks 
up new genes from a virus that usually infects birds or pigs .An avian strain named 
H5N1 raised the concern of new influenza pandemic, after it emerged in Asia in 
1990s,but it has  not evolved to a form that spreads easily between people. In April 
2009 a novel flu strain evolved that combined genes from human pig, and bird flu, 
initially dubbed ―SWINE FLU‖ and also known as influenza A/H1N1 emerged in 
Mexico, the united states and several other nation . 
The world health organization officially declared the outbreak to be pandemic 
on june11, 2009. The WHO’s declaration of a pandemic level 6 was an indication of 
spread, not severity, the strain actually having a lower mortality rate than common flu 
out breaks. 
 
Vaccinations against influenza are usually made available to people in 
developed countries. Farmed poultry is often vaccinated to avoid decimation of the 
flocks. The most common vaccine is the trivalent influenza vaccine (TIV) that contains 
purified and inactivated antigens against three viral strains. Typically, this vaccine 
includes, material from two influenza A virus subtypes and one influenza virus B strain 
.the TIV carries no risk of transmitting the disease ,and it has very low reactivity .A 
vaccine formulated for one year, may be ineffective in the following year ,since the 
influenza virus evolves rapidly, and new strains quickly replace the older ones. 
Antiviral drugs such as neuraminidase inhibitor OSELTAMIVIR have been used to 
treat influenza. 
                       Table:3 SIGNS AND SYMPTOMS 
Symptom Sensitivity Specificity 
Fever 68-86% 25-73% 
Cough 84-98% 7-29% 
Nasal 68-91% 19-41% 
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   Congestion :                                                                                                                                          
 Symptoms of influenza can start quite suddenly one to two days after 
infection.Usually the first symptoms are chills or a chilly sensation,but fever is also 
early common in the infection,with body temperatures ranging from 38-39⁰c.Many 
people are so ill that they are confined to bed for several days with aches and pains 
throughout their bodies,which are worse in their backs and legs.Symptoms of influenza 
include: 
 Fever and extreme coldness 
 Cough 
 Nasal congestion 
 Bodyaches, especially joints and throat 
 Fatigue 
 Headache 
 Irritated,watering eyes 
 Reddened eyes,skin(especially face)mouth,throat and nose 
 Petechial rash 
 In children,gastrointestinal symptoms such as diarrhea and abdominal pain 
 
            It can be difficult to distinguish between the common cold and influenza in the 
early stages of these infections,but a flu can be identified by a high fever with a sudden 
onset and extreme fatigue.diarrhea is normally not a symptom of influenza in 
adults,although it has been seen in the some human cases of the H5N1 ―bird flu‖and can 
be a symptom in children 
 
            Since antiviral drugs are effective in treating influenza ,if given early, it can be 
important to identify cases early .of the symptoms listed above, the combinations of 
fever with cough. Sore throat and/or nasal congestion can improve diagnostic accuracy. 
Two decision analysis studies suggest that during local outbreaks of influenza, the 
prevalence will be over 70%,and thus patients with any of these combinations of 
symptoms may be treated with neuraminidase inhibitors without testing .Even in the 
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absence of a local outbreak, treatment may be justified in the elderly during the 
influenza season as long as the prevalence is over 15%. 
 
 The available laboratory tests for influenza continue to improve. The 
United States Centers for  Disease Control and Prevention maintains an up-to-date 
summary of available laboratory tests 
 
 In virus classification Influenza viruses are RNA viruses that make 
up three of five genera belonging to the paramyxo virus family that are a common cause 
of respiratory infections in children such as croup,but can also cause a disease similar to 
influenza in adults. 
 
Influenza virus A 
 
 This genus has one species, influenza A virus. wild aquatic birds are 
the natural hosts for a large variety of influenza A, occasionally, viruses are transmitted 
to other species and may then cause devastating outbreaks in domestic poultry or give 
rise to human influenza pandemics. The type A viruses are the most virulent human 
pathogens among the three influenza types and cause the most severe disease. The 
influenza A virus can be subdivided in to different serotypes based on the antibody 
response to these viruses. The serotypes that have been confirmed in humans, ordered 
by the number of known human pandemic deaths, are: 
 
 H2N2, which caused Asian Flu in 1957 
 H1N1, which caused Spanish Flu in 1918 and Swine Flu in 2009 
 H3N2,which caused Hong Kong Flu in 1968 
 H5N1, which caused  Bird Flu in 2004 
 H7N7, which has unusual  zoonotic potential 
 H1N2, endemics in humans pigs and birds 
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Influenza virus B 
 This genus has one species, influenza B virus. Influenza B almost 
exclusively infects humans and is less common than influenza A.This type of influenza 
mutates at a rate 2-3 times slower than type A and is consequently is less genetically 
diverse,with only one influenza B  serotype. 
 
Influenza virus C 
 This genus has one species,influenza C virus,which infects humans 
,dogs and pigs, sometimes causing both severe illness and local epidemics.However, 
influenza C is less common than the other types and usually only causes mild disease in 
children 
 
Infection control 
 Reasonably effective ways to reduce the transmission of influenza 
include good personal health and hygienic habits such as not touching your eyes ,nose 
or mouth, frequent hand washing, covering coughs and sneezes, avoiding close contact 
with sick people, smoking raises the risk of contracting influenza, as well as producing 
more severe disease symptoms. 
                    Since influenza spreads through both aerosols and contact with 
contaminated surfaces. Alcohol is an effective sanitizer against influenza viruses, 
people with flu are advised to get plenty of rest, drink plenty of liquids. avoid using  
alcohol and tobacco. The two classes of antiviral drugs used against influenza are 
neuraminidase inhibitors and M2 protein inhibitors. Neuraminidase inhibitors are  
 
Neuraminidase inhibitors 
 Antiviral drugs such as oseltamivir (trade name tamiflu) and 
zanamivir(trade name  relenza) are neuraminidase inhibitors that are designed to halt the 
spread of virus in the body .These drugs may be effective against influenza A and B. 
Different strains of influenza viruses have differing degrees of resistance against these 
antivirals ,and it is impossible to predict  what degree of resistance a future pandemic 
strain might have. 
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M2 inhibitors 
 The antiviral  amantadine and rimantadine  block a viral ion channel 
and prevent the virus from infecting cells.These drugs are effective against influenza 
A.Measured resistance to amantadine and rimantadine in American isolates of H3N2 
has increased to 91%.This high level of resistance may be due to easy availability of 
amantadines. 
 
      Uncomplicated influenza is characterized by the abrupt onset of 
constitutional and respiratory signs and symptoms.However,in some persons,influenza 
can exacerbate underlying medical conditions or lead to secondary bacterial 
pneumonia.Epidemics of influenza occur during the winter months nearly every year 
.The main method for preventing influenza and its more severe complications is 
immunoprophylaxis with inactivated vaccine. Influenza specific antiviral drugs for 
chemoprophylaxis are an important adjunct to vaccine,but they are not a substitute for 
influenza vaccine.four antiviral agents are approved for preventing influenza 
 
           Amantadine and rimantadine are chemically related antiviral drugs active 
against influenza A virus but not influenza B virus .After influenza A viruses enter cells 
,these drugs inhibit the uncoating  of influenza A viruses by blocking the ion-channel 
activity of the viral M2 protein  
                  U.S.Food and drug administration are new members of a new class of 
antiviral agents that selectively inhibit the neuraminidase of both influenza A and B 
viruses .Neuraminidase inhibitors are analogues of sialic acid. Their proposed 
mechanism of action is to block the active site of neuraminidase and leave uncleaved 
sialic acid residues on the surfaces of host cells and influenza viral envelopes. Viral 
hemagglutinin binds to the uncleaved sialic acid residues, the result is viral aggregation 
at the host cell surface and a reduction in the amount of virus that is released and can 
infect other cells 
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         NA inhibitor-resistant viruses were thought to not readily emerge ,yet studies have 
demonstrated a higher prevalence of oseltamivir-resistant viruses than was expected 
among oseltamivir- treated patients. 
                   Emergence of influenza viruses with reduced susceptibility to 
neuraminidase inhibitors(NAIS) develops at a low level following drug treatment, and 
person-to-person transmission of resistant virus has not been recognized to date. The 
neuraminidase inhibitor susceptibility network was established to follow susceptibility 
of isolates and occurrence of NAI resistance at a population level in various parts of the 
world .Isolates from the WHO influenza collaborating centers were screened to 
susceptibility to oseltamivir and zanamivir by a chemiluminescent enzyme inhibition 
assay,and those considered potentially resistant were analyzed by sequence analysis of 
the neuraminidase genes. 
                 Viruses are the ultimate expression of parasitism they not only take nutrition 
from the host cell but also direct its metabolic machinery to synthesis new virus 
particles.Virus directed enzymes have been identified in the infected cell and some 
viruses have few enzymes of their own which may have higher affinities for some anti 
metabolites or inhibitors than the regular cellular enzymes. A virus is made up of a 
nucleic acid core enclosed in a protein coat called capsid which consists of repeating, 
identical subunits. Certain other constituents protect this nucleic acid moiety from the 
action of various body fluid enzymes.Viruses,unlike bacteria,have no cell wall,most 
viruses survive outside the host cell only for a short time, the major difficulties involved 
in viral infections. 
 A drug which acts on a virus in the cytoplasm may not necessarily 
act  on a virus that multiplies in the nucleus 
 The severity of infection produced by a virus and its response to a 
given drug differ considerably in different species 
 Precise diagnosis of many virus infections is difficult,further invitro 
efficacy of a new drug may not predict its therapeutic efficacy. 
 The antiviral compounds are likely to be most effective during the 
stage of multiplication of virus,which is difficult to detect. Viruses 
undergo structural changes and develop drug resistance. 
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 Unlike most antibiotics,antiviral drugs donot destroy their target 
pathogen, instead   they inhibit their development. 
                 Antivirals also can be found in essential oils of some herbs. 
 The emergence of antivirals is the product of a greatly expanded 
knowledge of the genetic and molecular functions of 
organisms,allowing the biomedical researchers understand the 
function and structure of viruses 
       
  Human H1N1 and H3N2 influenza A viruses are highly contagious 
and cause ―seasonal influenza world wide.Although human-to-human transmission is 
rare, once the H5N1viruses acquire the ability, a devastating pandemic may be 
inevitable. 
 
 Two countermeasures are available to control human 
influenza:Vaccination and antiviral treatment. Although vaccination plays a critical role 
in   prophylaxis, it makes more than six months to produce sufficient vaccine to cover a 
large proportion of the human population  upon the emergence of a new 
strain.Therefore, antivirals  are important tool to mitigate an influenza pandemic. 
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                             2. LITERATURE REVIEW 
 
Hoffmann-La Roche et al (2010).,
15
  Influenza is a transmissible viral pathogen that 
continues to cause substantial morbidity and mortality. Oseltamivir is an orally 
administered antiviral medication that selectively inhibits the influenza neuraminidase 
enzymes that are essential for viral replication. Treatment of infected children > or =1 
year and adults of all ages may decrease the severity and duration of the symptoms of 
infection, while prophylactic dosing can prevent their onset. Oseltamivir is ingested in 
the form of a prodrug (oseltamivir phosphate) that is rapidly converted by hepatic 
esterases into the active metabolite, oseltamivir carboxylate. Oseltamivir carboxylate 
has high bioavailability and penetrates sites of infection at concentrations that are 
sufficient to inhibit viral replication. The pharmacokinetics of oseltamivir and 
oseltamivir carboxylate are dose proportional after repeated doses of up to 500 mg 
twice daily. This predictable profile means that oseltamivir is suitable for use in diverse 
patient populations, which may include young children and elderly patients, various 
ethnic groups and those with renal or hepatic impairment. As the potential for drug 
interactions is low, oseltamivir is also suitable for use in patients with co-morbid 
conditions who are likely to be receiving concomitant medications. 
 
Osato H et al (2010).,
16 An efficient formal synthesis of oseltamivir phosphate 
(Tamiflu) has been achieved in 12 steps with use of the inexpensive and highly 
abundant D-ribose as the starting material. This concise alternative route does not 
utilize protecting groups and features the introduction of 3-pentylidene ketal as the 
latent 3-pentyl ether, the use of a highly efficient rcm reaction to form the Tamiflu 
skeleton, and selective functional group manipulations 
 
Lindemann L et al ( 2010).,
17 
Neuropsychiatric adverse events have been reported in 
influenza patients with and without exposure to oseltamivir (Tamiflu), triggering 
speculation as to whether oseltamivir may be interacting with any human receptors and 
contributing to such neuropsychiatric events. In this study, the in vitro selectivity profile 
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of oseltamivir prodrug and active metabolite was investigated. Both compounds lacked 
clinically relevant pharmacological activities on human, rodent and primate 
neuraminidases and on a panel of 155 other molecular targets, including those relevant 
for mood, cognition and behavior. Neuropsychiatric adverse events observed in 
influenza patients are likely a phenomenon caused by the infection rather than by 
oseltamivir. 
 
Laborde-Kummer E et al (2009).,
18
  A rapid and reliable capillary zone 
electrophoresis method was developed and validated for the assay of oseltamivir 
phosphate in capsules. Separation was carried out in fused silica capillary (60.2 cm total 
length and 10.0 cm effective length, 75 microm i.d.) by applying a potential of -15 kV 
at 25 degrees C. The selected electrophoretic buffer consisted of 50 mM sodium 
phosphate, pH 6.3 (direct UV detection, 226 nm). A short electrophoretic analysis time 
(less than 1.5 min) was obtained using the short end injection mode. The method was 
validated in terms of specificity, linearity, precision and accuracy. The RSD values 
were 0.94 and 0.98% for repeatability and intermediate precision, respectively. 
Recovery determinations allowed the calculation of a confidence interval from 98.64 to 
100.26% with a relative standard deviation value of 0.38%. LOD and LOQ were 
estimated at 0.97 and 3.24 microg/mL, respectively. The validated method was 
successfully applied to the determination of oseltamivir in three commercially available 
capsules (Tamiflu, Saiflu and Flufy). The results were in good agreement with those 
obtained by a HPLC method previously developed in our laboratory. This method 
presents advantages including short run time, simple and rapid sample preparation and 
no use of non-aqueous solvent throughout the analysis. 
 
Ogihara T et al (2009).,
19  Oseltamivir, an ester-type prodrug of the neuraminidase 
inhibitor[3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-
carboxylate phosphate (Ro 64-0802), has been developed for the treatment of A and B 
strains of the influenza virus but has neuropsychiatric and other side effects. In this 
study, we characterized the transport across intestinal epithelial cells and the absorption 
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of oseltamivir in rats. Uptake by Caco-2 cells (human carcinoma cell line) and HeLa 
cells transfected with peptide transporter 1 (HeLa/PEPT1) was time- and temperature-
dependent and was inhibited by typical PEPT1 inhibitors such as glycyl-sarcosine (Gly-
Sar). The uptake by Caco-2 cells and HeLa/PEPT1 was saturable, with similar K(m) 
values. Oseltamivir absorption in adult rats was greatly reduced by simultaneous 
administration of milk, casein, or Gly-Sar. Furthermore, the plasma and brain 
concentrations of oseltamivir were higher in fasting than in non fasting rats after oral 
administration. These results suggest that oseltamivir is a substrate of PEPT1 and that 
PEPT1 is involved in its intestinal absorption. 
 
Nie LD et al (2009).,
20
  Oseltamivir phosphate (1) was synthesized from (-)-shikimic acid 
through a short and practical synthetic route via eight steps in 47% overall yield. In 
addition, the highly regioselective and stereoselective nucleophilic replacement of OMs by 
the N(3) group in the third and seventh steps has been studied in detail, and the reaction 
conditions were optimized. 
 
Aydoğmuş Z et al (2009).,21  A new, simple and sensitive spectrofluorimetric method has 
been developed for the determination of oseltamivir phosphate (OSP) in capsules. The 
method is based on the reaction between oseltamivir and fluorescamine in borate buffer 
solution of pH 8.50 to give highly fluorescent derivatives that are measured  at 483 nm 
using an excitation wavelength of 381. The different experimental parameters effecting the 
development and stability of the reaction product were carefully studied and optimized. 
The fluorescence intensity concentration plot is rectilinear over the range 50-450 ng mL(-1) 
with a lower detection limit (LOD) of 1.219 ng mL(-1) and limit of quantitation (LOQ) of 
4.064 ng mL(-1). Selectivity was validated by subjecting stock solution of OSP to acidic, 
basic, oxidative, and thermal degradation. No interference was observed from excipients 
present in formulations. The developed method was successfully applied to determination 
of the drug in capsules. The mean % recovery (n = 6) was 100.08. The results obtained 
were in good agreement with those obtained using a reported spectrophotometric method. 
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Gong J et al (2008).,
22
  Oseltamivir phosphate (Tamiflu) is the only orally active anti-
influenza drug that potently inhibit neuraminidase. The recent emergence of avian flu, 
especially the H5N1 type, makes the situation of Tamiflu supply and demand increasingly 
serious. Further optimization of the current commercial approach and exploration of new 
synthetic routes are urgent. Here, different synthetic strategies of oseltamivir phosphate are 
reviewed, including discovery and improved synthetic route from (-)-quinic acid or (-)-
shikimic acid, new asymmetric synthesis via catalytic desymmetrization of a meso-aziridine 
(CDMA), Diels-Alder Reaction and from other available materials. 
 
Zutter U et al (2008).,
23
 A new, enantioselective synthesis of the influenza 
neuraminidase inhibitor prodrug oseltamivir phosphate 1 (Tamiflu) and its enantiomer 
ent-1 starting from cheap, commercially available 2,6-dimethoxyphenol 10 is described. 
The main features of this approach comprise the cis-hydrogenation of 5-(1-ethyl-
propoxy)-4,6-dimethoxy-isophthalic acid diethyl ester (6a) and the desymmetrization of 
the resultant all-cis meso-diesters 7a and 7b, respectively. Enzymatic hydrolysis of the 
meso-diester 7b with pig liver esterase afforded the (S)-monoacid 8b, which was 
converted into cyclohexenol 17 via a Curtius degradation and a base-catalyzed 
decarboxylative elimination of the Boc-protected oxazolidinone. Introduction of the 
second amino function via S(N)2 substitution of the corresponding triflate 18 with 
NaN3 followed by azide reduction, N-acetylation, and Boc-deprotection gave 
oseltamivir phosphate 1 in a total of 10 steps and an overall yield of approximately 
30%. The enantiomer ent-1 was similarly obtained via an enzymatic desymmetrization 
of meso-diester 7a with Aspergillus oryzae lipase, providing the (R)-monoacid ent-8a. 
 
Ono H et al (2008)., 
24
Oseltamivir phosphate (Tamiflu), an anti-influenza virus drug, is 
hydrolyzed by carboxylesterase to an active metabolite. The metabolite inhibits the 
influenza virus-specific neuraminidase. In this study, the effects of oseltamivir on 
normal core body temperature were studied in mice. Oseltamivir (30-300 mg/kg, 
intraperitoneally (i.p.) and 100-1000 mg/kg, orally (p.o.)) dose-dependently lowered the 
body temperature. The effects of oseltamivir (p.o.) continued longer than those of 
oseltamivir (i.p.), and approximately triple doses of oral oseltamivir were needed to 
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produce the same peak effects as intraperitoneal oseltamivir. The non-steroidal anti-
inflammatory drug diclofenac (1-30 mg/kg, i.p.) did not affect body temperature, and (at 
30 and 60 mg/kg, s.c.) did not interact with the hypothermic effects of oseltamivir (100 
mg/kg, i.p.). Zanamivir, which also inhibits neuraminidase, did not produce 
hypothermia at doses of 100 and 300 mg/kg, i.p. Clopidogrel (100, 300 mg/kg, i.p.), 
which is metabolized by the same carboxylesterase, tended to decrease the hypothermic 
effects of oseltamivir (100 mg/kg, i.p.). These results suggest that the hypothermic 
effects of oseltamivir are due to its hydrolytic metabolite, and that the hypothermia 
observed in mice has some relationship to the antipyretic effects and severe 
hypothermia (adverse event) observed in influenza patients after taking oseltamivir. 
 
Gholamreza Bahrami et al (2008).,25 This study was aimed at developing a fast 
and sensitive method for determination of oseltamivir carboxylic acid (OCA), the active 
moiety of anti influenza agent, oseltamivir phosphate, in human serum by high 
performance liquid chromatography and UV detection. The analyte and an internal 
standard (vanillin) were extracted from human serum by a solid phase extraction (SPE) 
procedure. Chromatographic separation was achieved using reverse phase C18 column 
with a mobile phase consisting of 0.05M phosphate buffer containing triethylamine (1 
mL/L; pH 3.0) and acetonitrile (70:30, v/v). The detection wavelength was set at 215 
nm. The average recoveries of the drug and internal standard were 98 and 85%, 
respectively. The calibration curve was linear over a concentration range of 15–6400 
ng/mL of OCA in human serum. The lower limits of detection and quantification were 5 
and 15 ng/mL, respectively. The coefficient variation values of both inter- and intra-day 
analysis were less than 12% whereas the percentage error was less than 4.5. The 
stability of the drug at the serum samples maintained at −40 ◦C for 60 days was found to 
be 100% from the initial value and no interferences were found from either endogenous 
components in serum or commonly co-administrated antiviral drugs. The validated 
method was applied to a randomized cross-over bioequivalence study of two different 
oseltamivir phosphate preparations in 24 healthy volunteers. 
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Aoki FY et al (2007).,
26
 Oseltamivir phosphate is a prodrug of oseltamivir carboxylate, 
a highly specific inhibitor of influenza virus neuraminidases. Given that oseltamivir 
carboxylate binds to highly conserved, essential amino acids in the catalytic site of the 
enzyme, and that the activity of neuraminidase is critical for virus release from infected 
cells and subsequent virus spread, the drug was expected to have a low propensity to 
select for viable resistant mutants. Indeed, viruses with neuraminidase (and 
haemagglutinin) substitutions conferring reduced susceptibility to oseltamivir have been 
generated with difficulty in vitro, and these mutants generally have reduced infectivity 
and transmissibility compared with wild-type virus in animal models. Studies of 
seasonal influenza isolates collected before the introduction of oseltamivir show an 
absence of naturally occurring resistance. Few resistant mutants have arisen during 
clinical trials of oseltamivir in seasonal influenza, with cumulative data from all Roche-
sponsored studies indicating an incidence of resistance of 0.32% in adults (0.4%, 
including low-level mutants detected by genotyping alone in mixed virus populations) 
and 4.1% (5.4%) in children. Higher incidences of resistance were observed in two 
small Japanese studies, in which children received a different dosing schedule from 
their Western counterparts. In summary, the overall incidence of influenza virus 
resistance associated with the seasonal use of oseltamivir is currently low and resistant 
viruses might be of little clinical significance, except perhaps in immune compromised 
individuals. However, continued vigilance, especially of emerging avian H5N1 strains, 
combined with careful, systematic laboratory-based monitoring, is essential. 
 
Joseph-Charles J et al (2007)., 
27 Oseltamivir phosphate (OP) is an antiviral drug that 
is used in the treatment and prophylaxis of both influenza A and influenza B. It is 
effective against all known influenza viruses than can infect humans, including 
pandemic influenza viruses and may be the most appropriate antiviral option against 
avian influenza caused by H5N1 virus. Tamiflu, the registered trademark used under 
exclusive license by Roche laboratories with OP as active pharmaceutical ingredient, is 
considered the best treatment for the bird flu disease. A simple, selective, linear, 
accurate and precise HPLC method was developed and validated for rapid assay of OP 
aimed to the quality control of Tamiflu capsules and generic versions. Isocratic elution 
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at a flow rate of 1.2 mL/min was employed on a Zorbax CN column (150 mm x 4.6mm; 
5 microm) at ambient temperature. The mobile phase consisted of methanol and 0.04 M 
formic acid pH 3.0 (50:50, v/v). The UV detection wavelength was 226 nm and 20 
microL of sample was injected. Sotalol hydrochloride was used as the internal standard 
(IS). The retention times for OP and IS were 3.40 and 2.25 min, respectively. The 
method was successfully applied to commercial pharmaceuticals, Tamiflu and generic 
versions. The proposed method could be applicable for routine analysis of OP and 
monitoring of the quality of marketed drugs as possibly counterfeit Tamiflu. 
 
Hill G et al (2002).,
28 Oseltamivir is an ester prodrug of the active metabolite 
[3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate 
phosphate (Ro 64-0802), a potent and selective inhibitor of neuraminidase enzyme of 
influenza virus. Oseltamivir is rapidly hydrolyzed by hepatic carboxyl esterases to Ro 
64-0802, which is then exclusively excreted by glomerular filtration and active tubular 
secretion without further metabolism. In vivo and in vitro studies were conducted to 
evaluate the renal drug-drug interaction potential of oseltamivir. Crossover studies were 
conducted in healthy subjects in which oral oseltamivir was administered alone and 
coadministered with probenecid, cimetidine, or amoxicillin. Probenecid completely 
blocked the renal secretion of Ro 64-0802, increasing systemic exposure (area under the 
curve) by 2.5-fold, but no interaction was observed with cimetidine or amoxicillin. 
These in vivo data show that Ro 64-0802 is secreted via an organic anion pathway, but 
Ro 64-0802 does not inhibit amoxicillin renal secretion. In vitro effects of Ro 64-0802 
on the human renal organic anionic transporter 1 (hOAT1) were investigated using 
novel Chinese hamster ovary cells stably transfected with hOAT1. Ro 64-0802 was 
found to be a low-efficiency substrate for hOAT1 and a very weak inhibitor of hOAT1-
mediated transport of p-aminohippuric acid (PAH). Ro 64-0802 did not inhibit the 
hOAT1-mediated transport of amoxicillin. In contrast, probenecid effectively inhibited 
the transport of PAH, Ro 64-0802, and amoxicillin via hOAT1. These in vitro 
observations are consistent with the in vivo data, validating the usefulness of the in vitro 
system for evaluating such drug-drug interaction. The study results demonstrate that 
oseltamivir has a low drug-drug interaction potential at the renal tubular level due to 
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inhibition of hOAT1.  
 
Gopal C.Gosh et al (2010).,
29
Oseltamivir phosphate(op;Tamiflu) is a prodrug of the 
anti-influenza neuraminidase inhibitor oseltamivir carboxylate(OC) and has been 
developed for the treatment and prevention of  both A and B strains of influenza.The 
recent increase in OP resistance in influenza A virus(H1N1;commonly called‖ 
swineflu‖)has raised the questions about the wide spread use of tamiflu in seasonal 
epidemics and the potential ecotoxicologic risk associated with its use in the event of a 
pandemic.The objectives of this study were to develop an analytical method for 
quantitative determination of OC in sewage treatment plant(STP) effluent and receving 
river water,and to investigate the occurrence of OC in STP effluent and river water in 
japan during a seasonal flu outbreak.An analytical method based on solid- phase 
extraction followed by liquid chromatography-tandem mass spectrometry.using this 
method,we analysed samples from three sampling campaigns conducted during the flu 
season.Results demonstrate that the highest concentration of OC detected in STP 
discharge was 293.3ng/l from a conventional activated-sludge-based STP;however ,we 
detected only 37.9ng/l from an advanced STP with ozonation as a tertiary treatment.In 
the receiving river water samples,we detected 6.6-190.2 ng/L OC,during the peak of the 
flu season.And concluded OC is present in STP in effluent and river water only during 
the flu season.Ozonation as tertiary treatment in STP  will substantially reduce the OC 
load in STP effluent during an influenza pandemic or epidemic. 
 ElenaA.Govorkal et al (2001).,30 The orally administered neuraminidase(NA)inhibitor 
was tested in parallel with zanamivir and oseltamivir against a panel of avian influenza 
viruses for inhibition of NA activity and replication in tissue culture.The agents were 
then tested for protection of mice against lethal H5N1and H9N2 virus infection.In 
vitro,RWJ-270201was highly effective against all nine NA subtypes.NA inhibition by 
RWJ-270201(50% inhibitory concentration,0.9 to 4.3nM) was superior to that by 
zanamivir and oseltamivir carboxylate.RWJ-270201inhibited the replication of avian 
influenza viruses in MDCK cells(50% effective concentration,0.5 to 11.8µm).Mice 
given 10mg of RWJ-270201per kg of bodyweight per day were completely protected 
against lethal challenge with influenza A(H5N1) and( H9N2)viruses.Both RWJ-270201 
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and oseltamivir significantly reduced virus titers in mouse lungs at daily dosages of 1.0 
and 10mg/kg and prevented the spread of virus to the brain.When treatment began 48hr 
after exposure to H5N1 virus,10mg of RWJ-270201 kg/day protected 50% of mice from 
death.These results suggest that RWJ-270201 is  at least as effective as either zanamivir 
or oseltamivir against avian influenza viruses and may be of potential clinical use for 
treatment of emerging influenza viruses that may be transmitted from birds to humans. 
 
Ashish Ashok Thatte et al (2011).,
31
 Oseltamivir phosphate is used in the treatment 
and prophylaxis of both influenza A and influenza B.In present investigation two simple 
and sensitive extractive photometric methods have been developed and validated for the 
determination of  Oseltamivir phosphate in bulk and capsule  dosage form.The 
developed methods involve formation of  extractable ion pair complex  of drug with 
bromocresol green and bromocresol purple dyes in acidic medium.Chloroform is used 
as extracting solvent for Bromocresol green and Bromocresol purple.Extractable 
complexes shows maximum absorption at 416nm and 404.5nm and the drug shows 
linearity range for Bromocresol green and Bromocresol purple in concentration range of 
8-28µg/ml.The coloured chromophores were found to be stable for 24hours.The effect 
of pH and dye concentration was also studied.
 
Zeynep Aydogmus et al (2010).,
32 A new,sensitive RP-HPLC method was developed 
for the determination of Oseltamivir phosphate in capsules and plasma.The 
method was based on the reaction of the drug with 4-chloro-7-nitrobenzofurazan 
in borate buffer solution of pH 8.50.Isocratic chromatography was performed on a 
C18 column with acetonitrile-10mM nitric acid as the mobile phase with 
Fluorescence detection.Mexiletine hydrochloride was used as an internal 
standard.Analytical parameters were evaluated.The calibration range was linear 
from 50.0-750.0ng/ml.The mean percentage recovery in capsules and plasma were 
99.95% and 95.42% respectively. 
 
Avramov-I.Ivicmilkal et al (2011).,
33
 A gold electrode was applied in the voltametric 
determination of oseltamivir phosphate standard in 0.05M NaHCO3.Oseltamivir 
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phosphate as a standard and as a component of Tamiflu capsule exhibited the identical 
cyclic voltamogram.The peaks originated from excipients in capsule do not appear 
under the applied electrochemical conditions.The electrochemical method for the 
qualitative determination of Oseltamivir phosphate in Tamiflu capsule by cyclic 
voltametry was developed.The presence of Oseltamivir phosphate as standard and as a 
content of Tamiflu capsule in electrolyte as well as their concentrations were 
simultaneously checked by HPLC.The lack of the current/concentration dependency 
was established.The not pretreated glassy carbon electrode cannot be used for the 
determination of oseltamivir phosphate under identical experimental conditions 
presented for gold electrode 
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3. AIM AND OBJECTIVE OF THE STUDY 
Aim : 
 The main aim of the study is to formulate and evaluate Oseltamivir phosphate 
capsules 75 mg. 
 
Objective : 
 The objective of the present study is to develop a pharmaceutically equivalent, 
low cost, quality improved and stable formulation of Oseltamivir Phosphate 
capsules. Oseltamivir is an orally administered antiviral medication that 
selectively inhibits the influenza neuraminidase enzyme that are essential for 
viral replication. 
 
Plan of the work : 
It was planned to carry out study in the sequence below:  
 Analysis of the dosage forms available in the market. 
 Preformulation Studies: Solubility and compatibility of studies 
 Formulation of Oseltamivir Phosphate capsules. 
 Evaluation of Oseltamivir Phosphate capsules. 
 Selection of the best formulation on the basis of in vitro drug release. 
 Comparision of best formulation with that of innovator. 
 Stability studies of Oseltamivir Phosphate capsules.  
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4.DRUG PROFILE 
 
Oseltamivir phosphate 
34,35,36,37 
 
Oseltamivir phosphate is an antiviral medication used to treat adults and 
children who have influenza (the flu) 
 
Structure 
 
  
Chemical formula : C16H28N2O4. 
Chemical name : (3R,4R,5S)-4-acetylamino-5-amino3(1- 
ethylpropoxy)-1-cyclohexene-1-carboxylic 
acid,ethyl ester, phosphate (1:1).  
  
Molecular weight                 :      312.4 for oseltamivir free base and  
     410.4 for oseltamivir phosphate salt. 
Description                           : Oseltamivir phosphate is a white crystalline    
solid  with a bitter taste.   
Solubility                              : Freely soluble in water and methanol. 
Category          : Antiviral[NEURAMINIDASE INHIBITOR ] 
Density                             :  1.22g/ml. 
Bulk density                      :  -0.15g/cm
3
 
pH
  
value             :  3.3 to 5.3 
Melting temperature       :   192 to 196°C 
Melting point              :   201-203°C  
Storage   :  stored at room temperature, 15-30 C (59-86 F). 
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Pharmacology  
 Oseltamivir is an antiviral drug, a neuraminidase inhibitor used in the 
treatment and prophylaxsis  of both influenza A and influenza B. 
Oseltamivir is a prodrug usually administered as phosphate, it is hydrolysed 
hepatically to the active metabolite, the free Carboxylate of Oseltamivir. 
Mechanism of action 
 Oseltamivir is an ethyl ester requiring ester hydrolysis for conversion to the 
active form, Oseltamivir carboxylate. The proposed mechanism of action of Oseltamivir 
is inhibition of influenza virus neuraminidase with the possibility of alteration of virus 
particle aggregation and release. 
Pharmacokinetics 
Absorption and Bioavailability : Oseltamivir is readily absorbed from the 
gastrointestinal tract after oral administration of Oseltamivir phosphate and is 
extensively converted predominantly by hepatic esterases to Oseltamivir carboxylate 
Atleast 75% of an oral drug reaches the systemic circulation as Oseltamivir 
carboxylate. Exposure to Oseltamivir is less than 5% of total exposure after oral dosing. 
Co-administration with food has no significant effect on the peak plasma 
concentration (551ng/ml under fasted conditions and 441ng/ml under fed conditions) 
and Area under curve (6218 ng.h/ml under fasted conditions and 6069 ng.h/ml under 
fed conditions) of Oseltamivir carboxylate. 
 
 Distribution  
The volume of distribution (Vss) of Oseltamivir carboxylate, following 
intravenous administration in 24 subjects, ranged between 23 and 26 liters.  
The binding of Oseltamivir carboxylate to human plasma protein is low 
(36%). The binding of Oseltamivir to human plasma protein is 42% which is significant 
to cause significant displacement base during interactions.  
 
Metabolism 
Oseltamivir is extensively converted to Oseltamivir carboxylate by esterase 
located  predominently in the liver. Neither Oseltamivir nor Oseltamivir carboxylate is 
substrate for, or inhibitor of, cytochrome P450 isomers. 
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Elimination  
Absorbed Oseltamivir is primarly (>90%) eliminated by conversion to 
Oseltamivir carboxylate. 
Half life   :  1-3 hrs (Oseltamavir) 
       6-10 hrs (Oseltamavir carboxylate) 
     Oseltamivir carboxylate is eliminated entirely  
     (99%) by renal excretion. 
Renal clearance   :  18.8 l/hr. 
Glomerular    : 7.5 l/hr. 
Filtration rate   Less than 20% of radio labelled dose is 
 eliminated in feaces. 
Dose  :  The recommended oral dose is 75 mg 
 Oseltamivir twice daily for 5 days. 
Strengths    :  30 mg, 45 mg and 75 mg.  
 
Adverse effects 
In treatment studies  in adult and adolescents aged 13 years and older, the most 
frequently reported adverse effects were nausea and vomiting, diarrhea, bronchitis, 
abdominalpain, dizziness, headache, cough, insomnia, vertigo, fatigue. 
      In prophylaxis studies in adult and adolescent patients,adverse events were similar. 
 
 Other Drug interactions 
 Four moderate drug interactions and three minor drug interactions,drug 
interactions of Oseltaltamivir phosphate.  
 Alimta,Ampicillin/probencid,Baraclude(entecavir),Benemid(probencid),
Entecavir,Flumist(influenza virus 
vaccine,live,trivalent)Premetrexed,Proben-c Probenecid and Colchicine. 
Safety 
    It is contraindicated in patients who have had severe allergic reactions such as 
anaphylaxis or serious skin reactions such as toxic epidermal necrolysis,erythema 
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multiforme,serious bacterial infections may begin with influenza like symptoms or may 
co-exists withy or occur as complications during the course of influenza. 
Storage 
Protect from heat,light and humidity. 
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Excipient profile  
 
Pregelatinised starch 
38
 
Nonproprietary Names 
BP : Pregelatinised Starch 
PhEur : Starch, Pregelatinised 
USP-NF   : Pregelatinized Starch 
Synonyms            :  Insta-Starch, Amylum pregelificatum, 
compressible starch. 
Chemical Name  :  Pregelatinized starch 
Empirical Formula             :  (C6H10O5)n  
Functional Category      :      Tablet and capsule diluents, tablet and capsule 
Disintegrant,  tablet binder. 
Applications in Pharmaceutical Formulation or Technology 
Partially pregelatinized starch is a modified starch used in oral capsule and 
tablet formulations as a binder, diluent,( Small LE et al., 1978) and 
disintegrant.  
 
Description 
Pregelatinized starch occurs as a moderately coarse to fine, white to off-
white colored powder. It is odorless and has a slight characteristic taste. 
Typical Properties 
Solubility   :  Practically insoluble in organic solvents.slightly    
 soluble in cold water,depending on degree of 
 pregelatinisation       
Density (bulk) : 0.586 g/cm3 
Density (tapped) : 0.879 g/cm3 
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Stability and Storage Conditions 
Pregelatinized starch is a stable but hygroscopic material, which should be 
stored in a well-closed container in a cool, dry place. 
Regulatory Status 
Included in the FDA Inactive Ingredients Database (oral capsules, 
suspensions, and tablets; vaginal preparations). Included in nonparenteral medicines 
licensed in the UK. 
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Croscarmellose Sodium
 38 
Synonyms                           :  Ac-Di-Sol; carmellosum natricum conexum; 
crosslinked carboxymethylcellulose sodium; 
Explocel; modified cellulose gum; Primellose; 
Solutab; Vivasol. 
Chemical Name  :         Cellulose, carboxymethyl ether, sodium salt.  
Empirical Formula           :      Croscarmellose sodium is a crosslinked polymer
     of   carboxymethylcellulose sodium.  
  
Functional Category : Tablet and capsule disintegrant 
Description :       Croscarmellose sodium occurs as an odorless,  
 white or   grayish-white powder. 
Typical Properties 
Density (bulk)  : 0.529 g/cm3 
Density (tapped)  : 0.819 g/cm3 
Solubility  :    Insoluble in water, although croscarmellose 
 sodium rapidly swells to 4–8 times its original 
 volume on contact with water. Practically 
 insoluble in acetone, ethanol and toluene. 
Stability and Storage Conditions 
Croscarmellose sodium is a stable though hygroscopic material. 
Regulatory Status 
Included in the FDA Inactive Ingredients Database (oral capsules,granules, 
sublingual tablets, and tablets). Included in nonparenteral medicines licensed in the UK. 
Included in the Canadian List ofAcceptable Non-medicinal Ingredients. 
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Povidone ( Chowdary KP et al., 1995)38,39 
 Synonyms   : Kollidon;Plasdonepolyvidone;  
Chemical Name  : 1-Ethenyl-2-pyrrolidinone homopolymer 
     polyvinylpyrrolidone; povidonum 
Empirical Formula  : (C6H9NO)n  
Functional Category :  Disintegrant; dissolution enhancer;  
suspending agent; tablet binder. 
Description                        :       Povidone occurs as a fine, white to creamy-white 
colored, odourless     or almost odourles spowder. 
Povidones with K-values equal to or lower than 30 
are manufactured by spray-drying and occur as 
spheres. Povidone K-90  and higher K-value 
povidones are manufactured by drum drying and 
occur as plates. 
 
Typical Properties  
Density (bulk)  : 0.29–0.39 g/cm3. 
Density (tapped)    : 0.39–0.54 g/cm3  
Solubility   : Freely soluble in acids, chloroform, ethanol(95%) 
ketones, methanol, and water; practically insoluble 
in ether, hydrocarbons, and mineral oil. 
 
Applications in Pharmaceutical Formulation or Technology 
Although povidone is used in a variety of pharmaceutical formulations, it is 
primarily used in solid-dosage forms. In tableting, povidone solutions are used as 
binders in wet-granulation processes. Povidone is used as a solubilizer in oral and 
parenteral formulations, and has been shown to enhance dissolution of poorly soluble 
drugs from solid-dosage forms. 
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Regulatory Status 
Accepted for use in Europe as a food additive. Included in the FDA 
Inactive Ingredients Database (IM and IV injections; ophthalmic preparations; oral 
capsules, drops, granules, suspensions, and tablets; sublingual tablets; topical and 
vaginal preparations). Included in non parenteral medicines licensed in the UK. 
Included in the Canadian List of Acceptable Non-medicinal Ingredients.  
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Talc 
38
 
Non proprietary Names   
BP    :  Purified Talc 
JP    :  Talc 
PhEur    :  Talc 
USP    :  Talc 
Synonyms   : Altalc; hydrous magnesium calcium silicate; 
      Hydrous magnesium silicate; Imperial; 
magnesium hydrogen metasilicate; 
Magsil Osmanthus; Magsil Star, 
purified French chalk; Purtalc; soapstone; steatite; 
Superiore; talcum.    
Chemical Name   : Talc 
Empirical Formula           : Mg6(Si2O5)4(OH)4 
Functional Category  : Anticaking agent; glidant; tablet and capsule 
                                  diluent; capsule lubricant. 
 
Applications in Pharmaceutical Formulation or Technology 
Talc was once widely used in oral solid dosage formulations as a lubricant 
and diluents. Talc is also used as a lubricant in tablet formulations;( Oetari RA., 2003) 
in a novel powder coating for extended-release pellets and as an adsorbant. 
Description 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is  soft to the touch and free from 
grittiness. 
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Typical Properties 
Solubility   : Practically insoluble in dilute acids and  
alkalis, Organic solvents, and water 
 
Regulatory Status 
Accepted for use as a food additive in Europe. Included in the FDA Inactive 
Ingredients Database (buccal tablets; oral capsules and tablets; rectal and topical 
preparations). Included in nonparenteral medicines licensed in the UK. Included in the 
Canadian List of Acceptable Non-medicinal Ingredients 
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Sodium stearyl fumerate 
38,40
 
Synonyms   :     Fumaric acid, octadecyl ester, sodium salt;natrii  
                   stearylis fumaras; Pruv; 
                   sodium monostearyl fumarate. 
Chemical Name  :     2-Butenedioic acimd,onooctadecyl ester,  
        sodium salt  
Empirical Formula  :       C22H39NaO4  
 Functional Category :     Tablet and capsule lubricant. 
 
Applications in Pharmaceutical Formulation or Technology 
Sodium stearyl fumarate is used as a lubricant in capsule and tablet 
formulations at 0.5–2.0% w/w concentration.( Holzer AW et al., 1997).  It is also used 
incertain food applications. 
Description 
Sodium stearyl fumerate is a fine, white powder with agglomerates of flat, 
circular-shaped particles. 
Typical Properties 
Density (bulk)  : 0.2–0.35 g/cm3 
Density (tapped)   : 0.3–0.5 g/cm3 
Solubility   : Acetone Practically insoluble 
Chloroform Practically insoluble 
Ethanol Practically insoluble 
Methanol Slightly soluble 
Regulatory Status 
GRAS listed. Permitted by the FDA for direct addition to food for human 
consumption as a conditioning or stabilizing agent in various bakery products, flour-
thickened foods,  processed cereals up to 0.2–1.0% by weight of the food. Included in 
nonparenteral medicines licensed in the UK. Included in the FDA Inactive Ingredients 
Database (oral capsules and tablets) 
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                               5.METHODOLOGY 
 
          Table: 4  List of materials 
  
Materials Manufacturers 
Oseltamivir phosphate 
 
 
Msn pharmaceuticals,Hyderabad. 
 
Pregelatinised Starch Colorcorn Asia Pvt Ltd,Mumbai. 
Croscarmellose sodium Signet chemical corporation,Mumbai. 
Povidone K-30 Signat chemical corporation,Mumbai. 
Talc Signat chemical corporation,Mumbai. 
Sodium stearyl fumerate J.R.S Pharma,Germany. 
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                         Table: 5   List of equipments 
S.No. Instruments Name Manufacturer 
1 
Mechanical stirrer Remi Mortors,Mumbai. 
2 
Tray Drier-TD6 Anchor Mark,Mumbai. 
3 
Tap Density Tester-ETD-1020 Electro Lab,Canada. 
4 
Electro Magnetic & Digital Shieve 
Shaker-EMS-8 
Electropharma,Banglore. 
5 
Moisture Analyzer-HG63 Toledo,Germany. 
6 
Disintegration Tester-ED 2AL Electro Lab,Canada. 
7 
Conta Bin Blender Anchor Mark ,Mumbai. 
8 
Rapid Mixer Granualator-RMG25 Anchor Mark ,Mumbai. 
9 
Fluid Bed Drier(Small) UMANG Pharma Tech, 
Maharastra. 
10 
Dissolution Tester USP-08L,12L Electro Lab,Canada. 
11 
UV-VisibleSpectrophotometer Agilent,Haryana. 
12 
Laboratory Oven NSW INDIA,Haryana. 
13 
p
H
 Meter Cyberscan, Banglore. 
14 
Laboratory Centrifuge Appratus-R4C Remi,Mumbai. 
15 
Water Bath Equitron,New Delhi. 
16 
Ultra Sonic Cleaner (Sonicator) Enertech,Canada. 
17 
HPLC with dual λ absorbance detector 
2487 
Waters,United States. 
18 
HPLC with R.I.Detector 2414 Waters,United States. 
19 
HPLC with photo array detector 2996 Waters,United States 
20 
K.F. Titrator Polymon,Japan. 
21 
Stability Chamber Thermo Lab,India 
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Pre-formulation studies 
Objective 
The overall objective of preformulation testing is to generate information useful 
in developing the formulation which is stable and bioavailable. Further the use of 
Preformulation parameters maximizes the chances in formulating an acceptable, safe, 
efficacious and stable product. For any drug substances to formulate in to a dosage form, 
it is necessary to study the physicochemical properties of the bulk drug like physical 
appearance, solubility, bulk density, tapped density, compressibility, melting point, 
molecular weight, sieve analysis. 
 
Physical Appearance 
The appearance of the API was done by visual observation 
 
Bulk Density: 
Bulk density of a compound varies substantially with the method of 
crystallization, milling or formulation. Bulk density is determined by pouring presieved 
blend into a graduated cylinder via a large funnel and measure the volume and weight as 
is given by  Bulk density =W/V0, 
          Bulk Density= Weight of the Blend/ Bulk Volume of the Blend 
                  W=weight of powder, V0=Initial volume  
Tapped Density: 
Tapped density is determined by placing a graduated cylinder containing known 
mass of blends on a mechanical tapped apparatus, which is operated for a fixed number of 
taps until the powder bed volume has reached a minimum volume. Using the weight of 
the drug in the cylinder and this minimum volume, the tapped density may be computed. 
Tapped Density=Weight of Blends/ Tapped Volume of Blends 
               Tapped density=W/Vf, W=weight of powder,F=final volume. 
Carr’s Index 
Carr’s Index is measured using the values of the bulk density and tapped density. 
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The following equation is used to find the Carr’s index 
  
                                    CI=(TD-BD)/TD*100 
Where, TD= Tapped Density,    BD= Bulk Density 
 
                      Table 6 Compressibility Index 
Compressibility  index Type of flow 
≤10 Excellent 
11-15 Good 
16-20 Fair 
21-25 Passable 
26-31 Poor 
32-37 Very poor 
>38 Very very poor 
 
Angle of Repose: 
The manner in which stresses are transmitted through a bed and beds response to applied 
stress reflected in the various angles of friction and response. The most commonly used of 
these is angles of response, which may be determined experimentally by a number of 
methods. The method used to find the angles of response is to pour the power in a conical 
heap on a level. Flat surface and measure the inclined angled with the horizontal pile. 
                                
    Tanθ =    
  Where hHeight of the heap 
          R  Radius of the heap. 
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                                Table 7 Angle of Repose  
Angle of repose (degrees) Flow property 
25-30 Excellent 
31-35 Good 
36-40 Fair 
41-45 Passable 
46-55 Poor 
56-65 Very poor 
>66 Very, Very poor 
 
Haussner’s Ratio 
Haussner’s ratio was determined as the ratio between the tapped density to that 
of the bulk density. 
                  Haussner’s ratio= ρt/ρo  
Where, ρt= Tapped Density,  
             ρ0= Bulk Density. 
                                 Table 8 Haussner’s Ratio  
Haussner’s ratio Type of flow 
1.00-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.59 Very poor 
>1.60 Very Very poor 
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Compatibility studies 
 
Samples were placed in 3 ml glass crimp-top ampoules. The reference cells were 
loaded with identical ampoules containing 200 mg of dry talc to balance the heat 
capacities. Before starting a series of experiments, all four calorimetric cells were 
calibrated using two-point static electrical calibration at 0 and 299.6µW. The samples 
and reference ampoules were sealed with fresh Teflon-lined closures just to starting the 
experiment and stored at 40⁰C,75%RH  for 28 days and 55⁰C for 14 days. 
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COMPATIBILITY STUDIES FOR OSELTAMIVIR PHOSPHATE 
CAPSULES 75mg. 
 Table 9 Compatability studies of Oseltamivir phosphate capsules 
S.NO INGREDIENTS RATIO QUANTITY 
(gm) 
2 WEEKS 4 WEEKS 
1 Oseltamivir Phosphate 1 2 NI NI  
2 Pregelatinised starch 1 2 NI NI 
3 Croscarmellose sodium 1 2 NI NI 
4 Povidone K-30 1 2 NI NI 
5 Talc 1 2 NI NI 
6 Sodium stearyl fumerate 1 2 NI NI 
7 Oseltamivir Phosphate + 
Pregelatinised starch 
1:0.5 4.5 : 2.07 NI NI 
8 Oseltamivir Phosphate + 
Croscarmellose sodium 
1:0.1 6:0.6 NI NI 
9 Oseltamivir Phosphate + 
Povidone K-30 
1:0.03 6:0.180 NI NI 
10 Oseltamivir Phosphate +talc  1:0.015 6:0.090 NI NI 
11 Oseltamivir Phosphate + Sodium 
stearyl fumerate 
1:0.015 6:0.090 NI NI 
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EVALUATION OF CAPSULES: 
 
A.Weight variation test:
 
 
Individual weights of 20 capsules were taken and the average weight was 
calculated by using the following formula. 
 
                                (Weight of capsule-Average weight)   
Weight variation = ----------------------------------------------- ×100 
                                      Average weight of capsules 
     Weight variation should not be ± 5 %. 
      WEIGHT VARIATION OF FORMULATIONS 
parameters F 1 F2 F3 F4 F5 F6 F7 
Weight 
variation(mg) 
210 218.4 223.2 223.9 225.11 235.3 225.3 
 
B. Content uniformity test: 
 The content of individual dosage complies with the test if not more than one 
individual content is outside the limits of 85 to 115 percent of the average content and 
none is outside the limits of 75 to 125 percent of the average content. The preparation 
fails to comply with the test if more than three individual contents are outside the limits 
of 85 to 115 percent of the average content or if one or more individual contents are 
outside the limits of 75 to 125 percent of the average content. 
C. Lock length 
It was tested by using vernier calipers. 
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LOCKED LENGTH OF FORMULATIONS  
Parameters F1 F2 F3 F4 F5 F6 F7 
Locking 
length(mm) 
17.6 18 18 18 18 18 18 
 
D. Moisture permeation test:  
 The USP requires determination of the moisture permeation characteristics of 
single unit and unit dose containers to assure their suitability for packing capsules. The 
degree and rate of moisture penetration is determined by packing the dosage unit 
together with a colour revealing desiccant pellet, exposing the packaged unit to known 
relative humidity over a specified time, observing the desiccant pellet for colour change 
(indicating desiccating absorption of moisture) and comparing the pre and post weight 
of the packaged unit and also by the Karl Fisher titration equipment. 
E. Disintegration 
              The compendial disintegration test for hard and soft capsules follows the same 
procedure and uses the same apparatus as used for uncoated tablets. The capsules are 
placed in the basket rack assembly, which is repeatedly immersed 30 times per minute 
in to a thermostatically controlled fluid at 37ºc and observed over the time described in 
the individual monograph. To fully satisfy the test the capsules disintegrate completely 
into a soft mass having no palpably firm core, and only some fragments of the gelatin 
shell.  
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DISINTEGRATION TIME 
Parameters F1 F2 F3 F4 F5 F6 F7 
Disintegration 
time(min) 
4.10 4.08 4.0 3.50 3.50 3.20 3.20 
 
DISSOLUTION AND DISSOLUTION TESTING 
DESIGN OF APPARATUS 
The ideal features of a dissolution apparatus are  
1. The fabrication, dimensions, and positioning of all components must be precisely 
specified and reproducible, run to run. 
 
2. The apparatus must be simply designed, easy to operate, and useable under a variety 
of conditions. 
 
3. The apparatus must be sensitive enough to reveal process changes and formulation 
differences but still yield repeatable results under identical conditions 
. 
4. The apparatus, in most cases, should permit controlled variable intensity of mild, 
uniform, nonturbulent liquid agitation. Uniform flow is essential because changes in 
hydrodynamic flow will modify dissolution 
. 
5. Nearly perfect sink conditions should be maintained. 
 
6. The apparatus should provide an easy means of introducing the dosage form into the 
dissolution medium and holding it, once immersed, in a regular reliable fashion. 
 
7. The apparatus should provide minimum mechanical abrasion to the dosage form 
(with exceptions) during the test period to avoid disruption of the microenvironment 
surrounding the dissolving form. 
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8. Evaporation of the solvent medium must be eliminated, and the medium must be 
maintained at a fixed temperature within a specified narrow range. Most apparatuses are 
thermostatically controlled at around 37⁰C-38⁰C. 
 
9. Samples should be easily withdrawn for automatic or manual analysis without 
interrupting the flow characteristics of the liquid. In the latter case, efficient filtering 
should be achieved. 
 
10. The apparatus should be capable of allowing the evaluation of disintegrating, 
nondisintegrating, dense or floating tablets or capsules, and finely powdered drugs 
 
11. The apparatus should allow good inter laboratory agreement. 
There are two principal types of apparatus design. One is based on limited volume that 
is constrained to the size of the container used. The second type uses a continuous flow 
cell to house the dosage form and permits constant replenishment of the dissolution 
fluids. 
 
Paddle Apparatus 
An apparatus described by Levy and Hayes may be considered the forerunner of 
the beaker method. It consisted of a 400 ml beaker and a three-blade, centrally placed 
polyethylene stirrer (5 cm diameter) rotated at 59 rpm in 250 ml of dissolution fluid (0.1 
N HCl). The capsule was placed down the side of the beaker and samples were removed 
periodically. In the pharmacopoeial apparatus 2—the paddle apparatus method— a 
paddle replaces the basket as the source of agitation. As with the basket apparatus, the 
shaft should position not more than 2 mm at any point from the vertical axis of the 
vessel and rotate without significant wobble.  A distance of 25 ^ 2 mm between the 
blade and the inside bottom of the vessel is maintained during the test. The metallic 
blade and shaft comprise a single entity that may be coated with a suitable inert coating 
to prevent corrosion. Again typical arrangements for the apparatus. The dosage form is 
allowed to sink to the bottom of the flask before rotation of the blade commences. 
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Sinkers are recommended to prevent floating of capsules and other floatable forms. A 
small, loose piece of nonreactive material (e.g., a few turns of wire helix) may be 
attached to the dosage form. Soltero et al. thoroughly examined the influence of sinker 
shapes on dissolution rates obtained from gelatin capsules. Although a stainless steel 
helix is officially recommended, alternative shapes can greatly affect the dissolution 
rates. 
 
DISSOLUTION STUDIES 
Dissolution is a process by which the disintegrated solid solute enters the 
solution. The test determines the time required for a definite percentage of the drug in a 
capsule to dissolve under specified conditions. 
The dissolution test was carried out in USP apparatus Type II (paddle) with 0.1 
N Hydrochloric acid as the dissolution medium. The samples were drawn at 5, 10, 15 
30, and 45 min. Fresh volume of the medium were replaced with the withdrawn volume 
to maintain the sink conditions. Samples withdrawn were analyzed for the percentage of 
drug released. 
 
Dissolution Parameters 
Dissolution Apparatus      :    USP Apparatus Type II (Paddle) 
Dissolution Medium        :    0.1N Hydrochloric acid 
 Volume            :    900 ml 
 Temperature                                    :    37±2
0
 C 
 Rpm                                                :    50    
 Sampling intervals (min)                 :    5, 10, 15, 30 and 45 
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Assay of OSELTAMIVIR PHOSPHATE capsules 
37
 
 
Assay procedure 
Solution A: Dissolve 6.8g of potassium dihydrogen phosphate in 980ml of water. 
Adjust with 1M potassium hydroxide solution to a pH of 6.0 and dilute with water to 
1L. 
 
Mobile phase : Methanol, acetonitrile, and solution A(245 : 135 : 620) 
 
Diluent : Methanol, Acetonitrile and 0.01N phosphoric acid (245 : 135 : 620 ) 
 
Standard solution : 1mg/ml of USP Oseltamivir phosphate RS in diluent. 
 
Sample solution :  Weigh the content of 20 capsules and mix. Prepare the equivalent of 
about 1mg of oseltamivir per mL, based on the label claim, by first dispersing a suitable 
portion of the powder in about 40% of the flask volume of the diluents, using an 
ultrasonic bath for about 20min, and diluting with diluents to volume.   Centrifuge an 
aliquot of this solution, and use the supernatant. 
 
CHROMATOGRAPHIC SYSTEM 
37
 
Detector   :  UV  
Column   :  4.6 mm × 150mm ; packing L7 
Column temp   :  Ambient 
Flow rate   :  1.0 ml / min 
Wave length  :   280 nm 
Injection Size  :  15 µl 
Run time  :           60min 
 
System suitability 
Sample : Standard solution 
 
 Suitability requiremennts 
The test is not valid unless the tailing factor is not more than 2.0, the column efficiency 
is not less than 2000 theoretical plates and the relative standard deviation for replicate 
injection is not more than 2.0 percent. 
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Analysis 
Samples : Standard solution and sample solution 
Calculate the percentage of C16H28N2O4 in the portion of capsule taken 
Result =  (ru/rs) x (cs/cu) x (Mr1/Mr2) x 100 
Where  
ru = Peak response from the sample solution 
rs = Peak response from the standard solution 
cs = Concentration of Oseltamivir in the sample solution (mg/ml) 
cu  =  Concentration of oseltamivir in the sample solution (mg/ml) 
Mr1 = Molecular weight of oseltamivir, 312.40 
Mr2 = Molecular weight of oseltamivir phosphate, 410.40 
Acceptance criteria = 90.0 % - 110.0 % 
ASSAY 
parameters F1 F2 F3 F4 F5 F6 F7 
Assay(%) 88.2 87.1 93.5 95.4 99.8 97.6 99.6 
 
Stability Study:
42
 
          For all the pharmaceutical dosage forms it is important to determine the stability 
of the dosage form. This will include storage at both normal and exaggerated 
temperature conditions, with the necessary extrapolations to ensure the product will, 
over its designed shelf-life, provide medication for absorption at the same rate as when 
originally formulated. The design of the formal stability studies for the drug product 
should be based on the knowledge of the behaviour and properties of the drug 
substances and formal stability studies on the drug substance. Specification which is list 
of tests, references to the analytical procedures and proposed acceptance criteria, 
including the concept of different acceptable criteria as mentioned in ICH guide lines 
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     PROCESS FLOWCHART 
 MATERIALS                                                                      PROCESS 
 
  
      
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
      Dispensing 
 
Raw materials 
Oseltamivir phosphate 
Pregelatinised Starch 
Croscarmellose Sodium 
Povidone k-30 
 
Sifting # 30 
 
 
 
Oseltamivir phosphate 
Pregelatinised Starch 
Croscarmellose Sodium 
Povidone k-30 
  
Mixing 
(100 rotations) 
Talc 
Sodium stearyl 
fumerate 
Lubrication 
Lubricated blend 
 
Capsule filling 
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Table 10 Formulation of Oseltamivir phosphate capsules 
 
 
 98.5mg of Oseltamivir phosphate ≈ 75 mg of Oseltamivir 
 
 
SNO INGREDIENTS mg/capsule 
  
F1 F2 F3 F4 F5 F6 F7 
1 
Oseltamivir 
phosphate 
98.5 98.5 98.5 98.5 98.5 98.5 98.5 
2 
Microcrystalline 
cellulose(101) 
40 38 - - - - - 
3 
Pregelatinised 
starch 
- - 48.5 46.2 45.5 44.5 45.5 
4 
Croscarmellose 
sodium 
7.5 7.5 7.7 10 10 10 10 
5 Povidone K-30 8 10 2.3 2.3 3 3 3 
6 
Sodium stearyl 
fumerate 
3 3 1.5 1.5 1.5 2 1.5 
7 Talc 3 3 1.5 1.5 1.5 2 1.5 
8 Purified water q.s q.s - - - - - 
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Wet granulation method (F1 & F2 )  
Wet granulation is a process of using a liquid binder to lightly agglomerate the 
powder mixture. The amount of liquid has to be properly controlled, as over-wetting 
will cause the granules to be too hard and under-wetting will cause them to be too soft 
and friable. Aqueous solutions have the advantage of being safer to deal with than 
solvent-based systems but may not be suitable for drugs which are degraded by 
hydrolysis. 
Procedure 
1. The active ingredient and excipients are weighed and mixed. 
2. The wet granulate is prepared by adding the liquid binder–adhesive to the powder 
blend and mixing thoroughly. Examples of binders/adhesives include aqueous 
preparations of cornstarch, natural gums such as acacia, cellulose derivatives such as 
methyl cellulose, gelatin, and povidone. 
3. Screening the damp mass through a mesh to form pellets or granules. 
4. Drying the granulation. A conventional tray-dryer or fluid-bed dryer are most 
commonly used. 
5. After the granules are dried, they are passed through a screen of smaller size than the 
one used for the wet mass to create granules of uniform size. 
Low shear wet granulation processes use very simple mixing equipment, and can take a 
considerable time to achieve a uniformly mixed state. High shear wet granulation 
processes use equipment that mixes the powder and liquid at a very fast rate, and thus 
speeds up the manufacturing process. Fluid bed granulation is a multiple-step wet 
granulation process performed in the same vessel to pre-heat, granulate, and dry the 
powders. It is used because it allows close control of the granulation process 
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Dry blending process ( F3 to F7 )  
43
        
 A dry, free-flowing mixture of resin with plasticizers and other additives prepared by 
blending the components under high shear at temperatures below the fluxing point. Dry 
blends are generally more economical than molding powders and pellets made by 
plasticating and extrusion. 
            The dry blending process begins with the receipt of the ingredients. The 
ingredients are typically stored until they are tested for conformance to 
specifications,including microbiological contamination. Since microbiological 
contaminants may be present in low numbers and may be non-randomly distributed 
within the lot, it is difficult to assure microbiological quality by lot testing alone. 
Therefore, manufacturers of dry-blended products try to develop and maintain close 
relationships with their ingredient suppliers. Each supplier must produce their product 
in a manner that assures that harmful bacteria will not contaminate the finished 
ingredient. This is usually accomplished by a combination of appropriate process 
controls and strict adherence to good manufacturing practices. 
Dry ingredients are blended in large batches (1, 000 to 5,000 lbs.) in a ribbon 
blender or other large scale blending equipment. The ingredients must be blended until 
the nutrients are uniformly distributed throughout the batch. The blended product is 
then passed through a sifter to remove oversize particles and extraneous material. The 
sifted product is then transferred to bags, totes or lined fibre board drums for storage. In 
some cases, the powder is transferred directly to the powder packaging line. At the 
packaging line, the powder is transferred to a filler hopper that feeds powder into the 
can filling line. Filled cans are flushed with inert gas, seamed, labelled, coded and 
packed into cartons. Typically, finished product is held until it undergoes a final check 
for conformance to specifications, including testing for microbiological contaminants. 
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                               RESULTS AND DISCUSSION 
 
                        Determination of  Flow properties 
 
Table :10       Formulation parameters of formulated physical mixtures of drug 
and excipient  
Formulation Blend Characterisation 
Angle of 
Repose(θ) 
Tap 
density(gm/ml) 
Bulk 
density(gm/ml) 
Carr’s 
index(%) 
Haussner’
s ratio 
F1 33.4±0.08 0.675±0.04 0.529±0.04 31.60±0.51 1.12±0.03 
F2 31.7±0.12 0.675±0.49 0.53±0.05 32.53±0.14 1.12±0.04 
F3 34.1±0.06 0.657±0.02 0.526±0.05 33.47±0.16 1.13±0.02 
F4 35.8±0.08 0.675±0.034 0.543±0.05 33.84±0.12 1.15±0.05 
F5 29.5±0.08 0.712±0.12 0.608±0.2 29.55±0.04 1.10±0.02 
F6 29.8±0.06 0.627±0.021 0.627±0.021 28.62±0.08 1.12±0.06 
F7 29.4±0.05 0.663±0.025 0.552±0.04 28.74±0.04 1.09±0.05 
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   Table . 12: In-vitro dissolution profile of F1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure:3 Dissolution profile of F1 
 
Discussion : In this F1 Wet granulation process was employed by using MCC (101) 
grade. Required fill weight of the capsule was not achieved in this trial 
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Time (min) 
Dissolution Profile F1 
Series1 
Series2 
SNO TIME(Min) % CDR 
%CDR OF 
INNOVATOR 
1 5 64.2 
68.8 
2 10 74.3 
90.9 
3 20 79.8 
95.4 
4 30 84.5 
96.0 
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Table . 13: In-vitro dissolution profile of F2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure:4 Dissolution profile of F2 
 
Discussion : In this F2 Wet granulation process was employed by using MCC 
(101)grade. Required fill weight of the capsule was achieved but the assay 
anddissolutionvalues are very low.  
 
 
       
     
 
SNO TIME(Min) % CDR 
%CDR OF 
INNOVATOR 
1 5 65.4 
68.8 
2 10 75.9 
90.9 
3 20 80.1 
95.4 
4 30 82.6 
96.0 
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Table . 14: In-vitro dissolution profile of F3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure:5 Dissolution profile of F3 
 
Discussion : The process  is changed from Wet granulation to direct filling of dry blend 
in to capsules. Pregelatinised starch is used. Dissolution and Assay values are better 
when compare to wet granulation 
 
 
 
 
 
 
SNO TIME(Min) % CDR 
%CDR OF 
INNOVATOR 
1 5 68.2 
68.8 
2 10 76.0 
90.9 
3 20 86.8 
95.4 
4 30 92.2 
96.0 
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     Table . 15: In-vitro dissolution profile of F4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure:6 Dissolution profile of F4 
 
Discussion : In F4 the Dissolution and Assay values were greater than the previous 
formulation but not matches with that of reference formulation 
 
 
 
SNO TIME(Min) % CDR 
%CDR OF 
INNOVATOR 
1 5 70.2 
68.8 
2 10 82.5 
90.9 
3 20 87.4 
95.4 
4 30 94.8 
96.0 
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  Table . 16: In-vitro dissolution profile of F5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                              
                                    Figure:7     Dissolution profile of F5 
 
 
 
 
 
Discussion : In this F5 the Dissolution and Assay values were greater than the previous 
formulation and shows better results than  that of reference formulation. 
 
 
SNO TIME(Min) % CDR 
%CDR OF 
INNOVATOR 
1 5 78.6 
68.8 
2 10 96.4 
90.9 
3 20 98.2 
95.4 
4 30 99.7 
96.0 
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       Table . 17: In-vitro dissolution profile of F6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure:8 Dissolution profile of F6 
Discussion : In this F6 both the glidants concentration were increased to higher 
concentration levels. There is no much variation in the Dissolution and Assay values to 
that of the reference formulation 
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Time (min) 
Dissolution profile of F6 
Series1 
Series2 
SNO TIME(Min) % CDR 
%CDR OF 
INNOVATOR 
1 5 76.5 
68.8 
2 10 89.8 
90.9 
3 20 96.6 
95.4 
4 30 97.4 
96.0 
 72 
 
 
 
Table No. 18: In-vitro dissolution profile of F7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure:9 Dissolution profile of F7 
 
Discussion : In this F7 batch size of the capsules were increased and the reproducibility 
of results to that of F5 were seen. 
 
 
   
                  
SNO TIME(Min) % CDR 
%CDR OF 
INNOVATOR 
1 5 74.4 
68.8 
2 10 96.7 
90.9 
3 20 97.9 
95.4 
4 30 99.5 
96.0 
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                         IDENTIFICATION OF OSELTAMIVIR PHOSPHATE BY  
 
                                                         IR SPECTROSCOPY 
                  The experimental work stated with raw material analysis of Oseltamivir 
phosphate was identified by infrared spectral analysis .the report  was given below. 
  
Figure-12 FTIR SPECTRUM OF OSELTAMIVIR PHOSPHATE  STANDARD 
                      Method:KBR 
 
      Figure-13  FTIR  SPECTRUM OF OSELTAMIVIR PHOSPHATE   API 
 
                  Method:KBR 
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Figure-14 COMPATIBILITY STUDIES OF OSELTAMIVIR PHOSPHATE 
WITH EXCIPIENTS 
   Method:KBR 
 
 
                
 The  IR peaks in the both,oseltamivir phosphate before compatibility and after 
compatibility,were found to be nearly same so the excipients were compatible with the 
drug.The correlation of the both the spectrum shows the compatibility of the drug with 
the excipients used.      
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                  TABLE:19 STABILITY STUDIES 
SN
O 
TEST RESULTS 
  STORAGE CONDITIONS 
  40°c/75%RH 25 °c/ 
60%RH 
  INIT IAL 
ANALYSIS 
IST 
MONTH 
2ND 
MONTH 
3RD 
MONTH 
3RD 
MONTH 
1 Description Carmel/pink 
coloured size 2 
capsules 
containing 
white to off 
white granular 
powder 
Carmel/p
ink 
coloured 
size 2 
capsules 
containin
g white 
to off 
white 
granular 
powder 
Carmel/pi
nk 
coloured 
size 2 
capsules 
containing 
white to 
off white 
granular 
powder 
Carmel/pi
nk 
coloured 
size 2 
capsules 
containing 
white to 
off white 
granular 
powder 
Carmel/pi
nk 
coloured 
size 2 
capsules 
containing 
white to 
off white 
granular 
powder 
2 Identificati
on 
Complies Complies Complies Complies Complies 
3 Water 
content 
 2.80% 3.56% 4.38% 3.13% 
4 Assay  101.60% 100.30% 99.00% 99.10% 
5 Dissolution  98.9 103.6 98.2 105.6 
6 Related 
substances 
     
 % of 
impurity A 
 0.04% 0.08% 0.08% 0.03% 
 % of 
impurity B 
 0.09% 0.09% 0.08% 0.01% 
 % single 
max 
unknown 
impurity 
 0.02% 0.03% 0.04% 0.10% 
 % of total 
impurity 
 0.18% 0.29% 0.40% 0.19% 
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STABILITY STUDIES: 
     The purpose of stability studies is to provide evidence on how the  quality of a drug 
substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature ,humidity etc 
OBJECTIVE 
     To generate documented evidence that the tablets manufactured comply with  the 
finished product signification s under accelerated and long term stability conditions 
DESIGN PLAN 
ACCELERATED STUDY:-the product is subjected to accelerated stability studies at 
55⁰c for 2weeks and 40⁰c ±5%RH for 6months 
LONG TERM STUDY:- 
The product is subjected to long term studies at 25⁰ c± 2⁰ c/60%±5%RH for 12 months 
PACKAGE TYPE:- 
The tablets were packed as 30’s count in HDPE containers,induction sealed with 
adsorbent cotton 
TaBLE:20      SAMPLING  WITH DRAWAL SCHEDULE 
 
s.no Storage condition Test period 
1 40⁰C±2⁰C/75%±5%RH 1month 
 2month 
3month 
2 25⁰C±2⁰C/60%±5%RH 3months 
 
Related compounds  
A.(3S,4R,5s)-ethyl 4- acetamido-5-amino-2- azido-3( pentan-3-yloxy) cyclohexane 
carboxylated B. Tri butyl phospine oxide. 
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                                              9. SUMMARY 
The purpose of the present study was to develop and characterize a generic 
product of Oseltamivir phosphate capsules of strength 75mg comparable to the 
innovators product. 
Dry blending process was chosen to develop a finished pharmaceutical product 
Various formulation trials (F1-F7) were taken. In these trials, Drug: Excipient ratio was 
varied and the effect of Diluent, Disintegrant and Lubricant on the performance of both 
blend as well as on the physical and chemical parameters were studied. 
Formulation F1 was carried out by using Microcrystalline cellulose(101) as 
diluents through Wet granulation process but the required fill weight of the capsules 
were not achieved. In F2 formulation the capsule fill weight was achieved by altering 
the concentration of the diluents and the binder.In F3-F7 formulations dry blending 
process were employed and the Pre-gelatinised starch were used. In F3-F4 formulations 
the assay and dissolution were not satisfactory.In F3-F5 formulation the amount of Pre-
gelatinised starch and crosscarmellose sodium were altered.In this F5 formulation good 
results were achieved when compared to that of the reference product.In F6 formulation 
the glidant concentration were increased but there is no variation in the results.In F7 
formulation reproducibility of results were observed with the large batch size.  
The formulation F5 were considered as the optimised trial of all the trials. The 
Dissolution and Assay results of F5 were good when compared with the reference 
product. . The batch F5 was loaded for long term and accelerated stability studies at 25 
± 2C/60±5% RH and 40±2C/75±5% RH. The results of stability data for 1st and 2nd 
and 3
rd
 month were found to be good.                   
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                               10. CONCLUSION 
Oseltamivir phosphate is widely used as Anti-viral agent. They are formulated as 
Oseltamivir phosphate capsules which show better patient acceptability and compliance 
as conventional dosage forms. 
Based on various studies carried out we arrived at the following conclusions: 
Dry blending process was the preferred technology for the preparation of 
Oseltamivir phosphate capsule. 
Based on the preliminary studies various formulation trials (F1-F7) were carried 
out with different concentrations of disintegrants, lubricants. From the various 
formulations it was concluded that the formulation batch of F5 was finalised as the 
optimized formula. 
Formulation F5 showed satisfactory results with various physicochemical 
evaluation parameters like Disintegration time, Dissolution profile, Assay when 
compared with the marketed product. When subjected to accelerated stability studies the 
capsules were found to be stable. 
Infrared spectrum of the sample was found to be in compliance with the 
spectrum obtained from reference sample.The spectrum of reference of oseltamivir 
phosphate shown in figure no:12,and the spectrum of reference of sample of oseltamivir 
phosphate shown in figure no:13.Both show the characteristic transmittance in the range 
of 1800 cm
-1 
to 2000cm
-1. 
Compatibility studies with Excipients; 
The physical observation had shown that there is no colour change in all 
conditions,It shows there is no interaction in figure 14,shows that the FTIR  spectra of 
plain oseltamivir phosphate and oseltamivir phosphate with excipients. 
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